 |
Free
Access to abstracts at PubMed
PUBLICATIONS
- Liu C, Zhang Y, Liu, M, Zhou, H, Chowdhury WH, Lupold S, DeWeese TL,
Rodriguez R. Evaluation of continuous low dose rate versus acute single
high dose rate radiation combined with oncolytic viral therapy for prostate
cancer. Int J Radiat Biol. In Press
- Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi1 AH, Chowdhury WE,
Kudrolli TA, Yegnasubramanian A, Luo J, Rodriguez T, Mendell JT, Lupold SE.
miR-21: An androgen receptor regulated microRNA which promotes hormone
dependent and independent prostate cancer growth. [Priority Report] Cancer
Research; (69): 18, September 15, 2009.
- Chen Y, Foss C, Byun Y, Nimmagadda S, Pullambhatla M, Fox J,
Castanares M, Lupold SE, Babich J, Mease R, and Pomper M. Radiohalogenated
Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for
Prostate Cancer. J Med Chem. 2008 Dec 25;51(24):7933-43.
- Banerjee S., Foss, C., Castanares M., Mease R., Byun Y., Fox J.,
Hilton J., Lupold SE., Kozikowski A., Pomper M. Radiology Synthesis and
Evaluation of Technetium-99m- and Rhenium-labeled Inhibitors of the
Prostate-specific Membrane Antigen (PSMA). J Med Chem. 2008 Aug
14;51(15):4504-17
- Lupold SE.*, Kudrolli T., Chowdhury W., Wu P, and Rodriguez R. ~SA
Novel Method for Generating and Screening Peptides and Libraries Displayed
on Adenovirus Fiber~T Nucl. Acids Res. 2007 Oct; 35(20):e138, 1-10.
*Corresponding Author
- Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabula A,
Hsieh JT , Berge M, Ketner G, Lupold SE and Rodriguez R ~SAndrogen Receptor
Attenuation of Ad5 Replication: Implications for the Development of
Conditionally Replication Competent Adenoviruses~T Mol Ther. 2007
Aug;15(8):1495-503.
- Höti N, Chowdhury W, Hsieh JT, Lupold SE, and Rodriguez R ~SValproic
acid, a Histone Deacetylase Inhibitor, Is an Antagonist for Oncolytic
Adenoviral Gene Therapy~T Mol Ther. 2006 Dec;14(6):768-78.
- Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BYM, Lupold SE, Rodriguez R ~SValproic Acid Inhibits Invasiveness in
Bladder Cancer, but not in Prostate Cancer Cells~T Pharmacol Exp Ther. 2006
Nov;319(2):533-42.
- Lupold SE.*, Rodriguez R. Disulfide-Constrained Peptides that Bind
to the Extracellular Portion of the Prostate Specific Membrane Antigen. Mol
Cancer Ther, 3(5):597-603, May 1 2004. *Corresponding Author
- Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya
M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M,
Forrester KS, Harris CC. p53-induced up-regulation of MnSOD and GPx but not
catalase increases oxidative stress and apoptosis. Cancer Research,
64(7):2350-6, 2004
- Lupold SE.*, Hicke BJ., Lin Y., Coffey DS. Identification and
characterization of nuclease-stabilized RNA molecules that bind human
prostate cancer cells via the prostate-specific membrane antigen. Cancer
Research, 62(14):4029-33, 2002. *Corresponding Author
- Wang XW., Vermeulen W., Coursen JD., Gibson JD., Lupold SE.,
Forrester K., Xu GW., Elmore L., Yeh H., Hoeijmakers JHJ., Harris CC., The
XPB and XPD DNA helicases are components of the p53-mediated apoptosis
pathway. Genes and Development 10(10): 1219-1232, 1996
- Forrester K., Ambs S., Lupold SE., Kapust RB., Spillare EA.,
Weinberg WC., Felleybosco E., Wang XW., Geller DA., Tzeng E., Billiar TR.,
Harris CC., 1996. Nitric oxide-induced p53 accumulation and regulation of
inducible nitric oxide synthase expression by wild-type p53. Proc. Natl.
Acad. Sci. USA 93(6): 2442-2447, 1996
- Forrester, K., Lupold SE., Ott VL., Chay CH., Band V., Wang XW.,
Harris CC., 1995. Effects of p53 mutants on wild-type p53-mediated
transactivation are cell type dependant. Oncogene 10(11): 2103-11, 1995
|
|
|
|
